Check Out What Whales Are Doing With TEVA

High-rolling investors have positioned themselves bearish on Teva Pharmaceutical Indus TEVA, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in TEVA often signals that someone has privileged information.

Today, Benzinga's options scanner spotted 11 options trades for Teva Pharmaceutical Indus. This is not a typical pattern.

The sentiment among these major traders is split, with 36% bullish and 63% bearish. Among all the options we identified, there was one put, amounting to $53,560, and 10 calls, totaling $634,320.

Projected Price Targets

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $11.5 and $12.0 for Teva Pharmaceutical Indus, spanning the last three months.

Volume & Open Interest Development

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.

This data can help you track the liquidity and interest for Teva Pharmaceutical Indus's options for a given strike price.

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Teva Pharmaceutical Indus's whale activity within a strike price range from $11.5 to $12.0 in the last 30 days.

Teva Pharmaceutical Indus Call and Put Volume: 30-Day Overview

Noteworthy Options Activity:

About Teva Pharmaceutical Indus

Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.

Present Market Standing of Teva Pharmaceutical Indus

• With a volume of 5,571,065, the price of TEVA is down -0.42% at $11.86.
• RSI indicators hint that the underlying stock may be approaching overbought.
• Next earnings are expected to be released in 2 days.

Expert Opinions on Teva Pharmaceutical Indus

In the last month, 3 experts released ratings on this stock with an average target price of $13.666666666666666.

• An analyst from Barclays has decided to maintain their Overweight rating on Teva Pharmaceutical Indus, which currently sits at a price target of $15.
• Showing optimism, an analyst from Piper Sandler upgrades its rating to Neutral with a revised price target of $12.
• Showing optimism, an analyst from Jefferies upgrades its rating to Buy with a revised price target of $14.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Teva Pharmaceutical Indus options trades with real-time alerts from Benzinga Pro.